Safety and antibody response to inactivated COVID-19 vaccine in patients with chronic hepatitis B virus infection

作者全名："He, Taiyu; Zhou, Yingzhi; Xu, Pan; Ling, Ning; Chen, Min; Huang, Tianquan; Zhang, Biqiong; Yang, Ziqiao; Ao, Ling; Li, Hu; Chen, Zhiwei; Zhang, Dazhi; Shi, Xiaofeng; Lei, Yu; Wang, Zhiyi; Zeng, Weiqun; Hu, Peng; Lan, Yinghua; Zhou, Zhi; Kang, Juan; Huang, Ying; Shi, Tongdong; Pan, Qingbo; Zhu, Qian; Ran, Xiping; Zhang, Yingzhi; Song, Rui; Xiang, Dejuan; Xiao, Shuang; Zhang, Gaoli; Shen, Wei; Peng, Mingli; Cai, Dachuan; Ren, Hong"

作者地址："[He, Taiyu; Zhou, Yingzhi; Xu, Pan; Ling, Ning; Chen, Min; Huang, Tianquan; Zhang, Biqiong; Yang, Ziqiao; Ao, Ling; Li, Hu; Chen, Zhiwei; Zhang, Dazhi; Shi, Xiaofeng; Lei, Yu; Wang, Zhiyi; Zeng, Weiqun; Hu, Peng; Lan, Yinghua; Zhou, Zhi; Kang, Juan; Huang, Ying; Shi, Tongdong; Pan, Qingbo; Zhu, Qian; Ran, Xiping; Zhang, Yingzhi; Song, Rui; Xiang, Dejuan; Xiao, Shuang; Zhang, Gaoli; Shen, Wei; Peng, Mingli; Cai, Dachuan; Ren, Hong] Chongqing Med Univ, Affiliated Hosp 2, Dept Infect Dis, Inst Viral Hepatitis,Minist Educ,Key Lab Mol Biol, Chongqing, Peoples R China"

通信作者："Peng, ML; Cai, DC; Ren, H (通讯作者)，Chongqing Med Univ, Inst Viral Hepatitis, Chongqing 400000, Peoples R China."

来源：LIVER INTERNATIONAL

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:000761632600001

JCR分区：Q1

影响因子：6.7

年份：2022

卷号：42

期号：6

开始页：1287

结束页：1296

文献类型：Article

关键词：antibody response; CHB; cirrhosis; COVID-19 vaccine; safety

摘要："Background and Aims The safety and antibody responses of coronavirus disease 2019 (COVID-19) vaccination in patients with chronic hepatitis B (CHB) virus infection is still unclear, and exploration in safety and antibody responses of COVID-19 vaccination in CHB patients is significant in clinical practice. Methods 362 adult CHB patients and 87 healthy controls at an interval of at least 21 days after a full-course vaccination (21-105 days) were enrolled. Adverse events (AEs) were collected by questionnaire. The antibody profiles at 1, 2 and 3 months were elucidated by determination of anti-spike IgG, anti-receptor-binding domain (RBD) IgG, and RBD-angiotensin-converting enzyme 2 blocking antibody. SARS-CoV-2 specific B cells were also analysed. Results All AEs were mild and self-limiting, and the incidence was similar between CHB patients and controls. Seropositivity rates of three antibodies were similar between CHB patients and healthy controls at 1, 2 and 3 months, but CHB patients had lower titers of three antibodies at 1 month. Compared to healthy controls, HBeAg-positive CHB patients had higher titers of three antibodies at 3 months (all P < .05) and a slower decline in antibody titers. Frequency of RBD-specific B cells was positively correlated with titers of anti-RBD IgG (OR = 1.067, P = .004), while liver cirrhosis, antiviral treatment, levels of HBV DNA, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) and total bilirubin (TB) were not correlated with titers of anti-RBD IgG. Conclusions Inactivated COVID-19 vaccines were well tolerated, and induced effective antibody response against SARS-CoV-2 in CHB patients."

基金机构："National Natural Science Foundation of China [81772198]; National Science and Technology Major Project [2017ZX10202203-007, 2017ZX10202203-008, 2018ZX10302206-003]; Natural Science Foundation of Chongqing [cstc2020jcyj-msxmX0389]; a pilot project of clinical cooperation between traditional Chinese and western medicine for significant and complicated diseases of National Administration of Traditional Chinese Medicine: hepatic fibrosis"

基金资助正文："a pilot project of clinical cooperation between traditional Chinese and western medicine for significant and complicated diseases of National Administration of Traditional Chinese Medicine: hepatic fibrosis; National Natural Science Foundation of China, Grant/Award Number: 81772198; National Science and Technology Major Project, Grant/Award Number: 2017ZX10202203-007, 2017ZX10202203-008 and 2018ZX10302206-003; Natural Science Foundation of Chongqing, Grant/Award Number: cstc2020jcyj-msxmX0389"